In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Tuesday, November 10
European Commission Expands Melflufen Label to Third-Line Multiple MyelomaCancerNetwork (EUA) · 17:38 Acesso e saúde públicaEUAData from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
Gilead at Wolfe Healthcare Conference: anito-cel launch in focus By Investing.comInvesting.com India (EUA) · 17:07 TratamentosEUA
Monday, November 9th
Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple MyelomaOncLive (EUA) · 21:41 TratamentosEUAThe decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Diagnosis of Multiple Myeloma Through an Atypical Serum Protein Electrophoresis Profile: A Case ReportCureus (EUA) · 20:01 OutrasEUA
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaOncLive (EUA) · 14:06 TratamentosEUADuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Friday, November 6th
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAIDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Wednesday, 11/04
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)Karyopharm (EUA) · 14:04 Doentes e associaçõesEUA– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026...
Treatment After Early Relapse and Real-World Evidence in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.
Myeloma's Gray Zones: Sequencing, Oral Therapy, and FrailtyOncology Nursing News (EUA) · 08:00 Acesso e saúde públicaEUAAt the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.
Emerging Therapies and Supportive Care Advances in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma.
CD38-Targeted Immuno-PET Helps Detect Active Multiple MyelomaCancerNetwork (EUA) · 08:00 Doentes e associaçõesEUAIn a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
